Immunomedics Inc (IMMU)

11.47
NASDAQ : Health Care
Prev Close 11.45
Day Low/High 11.25 / 11.49
52 Wk Low/High 2.02 / 12.96
Avg Volume 2.39M
Exchange NASDAQ
Shares Outstanding 134.49M
Market Cap 1.54B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology

Immunomedics Announces Results Of Special Stockholder Meeting

Immunomedics Announces Results Of Special Stockholder Meeting

Obtains stockholder approval to increase authorized capital stock

Commit To Purchase Immunomedics At $4, Earn 12.5% Using Options

Investors eyeing a purchase of Immunomedics, Inc. shares, but tentative about paying the going market price of $7.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.

Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments

Closes on $125 million private placement financing with institutional investors

Immunomedics, Seattle Genetics Scrap License Deal

Immunomedics, Seattle Genetics Scrap License Deal

Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.

Immunomedics Delivers Business Updates, Announces Private Placement Offering And Outlines Strategic Steps To Drive Stockholder Value

Immunomedics, Inc. , (NASDAQ:IMMU) ("Immunomedics" or "the Company") today delivered several business and leadership updates and outlined a new strategic plan to drive long-term value for stockholders.

Bullish and Bearish Reversals for This Week

Bullish and Bearish Reversals for This Week

Financial names populate the bullish side.

Short Interest In Immunomedics Moves 12.2% Higher

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,898,519 share increase in total short interest for Immunomedics, Inc. , to 26,651,574, an increase of 12.20% since 03/15/2017.

Biotech Movers: Paratek Spikes 34%

Biotech Movers: Paratek Spikes 34%

Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Biotech Premarket Movers: Arena, Immunomedics, Aralez

Biotech Premarket Movers: Arena, Immunomedics, Aralez

Arena Pharmaceuticals, Immunomedics and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

Activist VenBio Wins Control of Immunomedics Board

Activist VenBio Wins Control of Immunomedics Board

VenBio gained four seats on Immunomedics' board of directors.

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.

Stockholders Endorse VenBio's Case For Meaningful Change At Immunomedics

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

TheStreet Quant Rating: D- (Sell)